Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 14 | 2021 | 512 | 4.400 |
Why?
|
| Hepatitis C | 11 | 2022 | 210 | 3.870 |
Why?
|
| Hepatitis C, Chronic | 7 | 2020 | 126 | 2.800 |
Why?
|
| Hepacivirus | 5 | 2022 | 160 | 1.600 |
Why?
|
| Gastroenterology | 4 | 2021 | 140 | 1.400 |
Why?
|
| Lactulose | 1 | 2023 | 20 | 0.940 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 42 | 0.920 |
Why?
|
| Liver Diseases | 2 | 2016 | 241 | 0.840 |
Why?
|
| Internship and Residency | 4 | 2021 | 1010 | 0.810 |
Why?
|
| Ribavirin | 2 | 2013 | 58 | 0.810 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2021 | 5 | 0.800 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2021 | 19 | 0.790 |
Why?
|
| Off-Label Use | 2 | 2014 | 16 | 0.590 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 394 | 0.560 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 32 | 0.530 |
Why?
|
| Interferon-alpha | 2 | 2013 | 234 | 0.530 |
Why?
|
| Informed Consent | 2 | 2020 | 266 | 0.520 |
Why?
|
| Viral Load | 2 | 2021 | 150 | 0.490 |
Why?
|
| Medicaid | 1 | 2017 | 217 | 0.490 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 364 | 0.470 |
Why?
|
| Interferons | 1 | 2014 | 133 | 0.470 |
Why?
|
| Drug Discovery | 1 | 2013 | 103 | 0.410 |
Why?
|
| Liver Transplantation | 4 | 2023 | 1271 | 0.390 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 34 | 0.390 |
Why?
|
| Curriculum | 4 | 2021 | 543 | 0.390 |
Why?
|
| Resource Allocation | 1 | 2011 | 65 | 0.390 |
Why?
|
| Humans | 28 | 2023 | 86678 | 0.380 |
Why?
|
| Health Care Rationing | 1 | 2011 | 83 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 351 | 0.380 |
Why?
|
| Patient Participation | 1 | 2012 | 216 | 0.380 |
Why?
|
| Treatment Outcome | 8 | 2021 | 7998 | 0.350 |
Why?
|
| Liver Cirrhosis | 3 | 2016 | 300 | 0.320 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 311 | 0.270 |
Why?
|
| United States | 7 | 2021 | 6681 | 0.260 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 372 | 0.250 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 76 | 0.210 |
Why?
|
| United States Food and Drug Administration | 2 | 2014 | 127 | 0.210 |
Why?
|
| Proline | 2 | 2013 | 57 | 0.210 |
Why?
|
| Viremia | 1 | 2021 | 55 | 0.200 |
Why?
|
| Oligopeptides | 2 | 2013 | 179 | 0.190 |
Why?
|
| Donor Selection | 1 | 2021 | 68 | 0.190 |
Why?
|
| Azathioprine | 1 | 2021 | 125 | 0.190 |
Why?
|
| Prednisone | 1 | 2021 | 258 | 0.190 |
Why?
|
| Beneficence | 1 | 2020 | 33 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2021 | 2264 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 895 | 0.180 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1015 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 456 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2021 | 352 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 747 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2021 | 306 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2021 | 464 | 0.160 |
Why?
|
| Female | 10 | 2021 | 44550 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 456 | 0.150 |
Why?
|
| Legislation, Drug | 1 | 2017 | 7 | 0.150 |
Why?
|
| Paracentesis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Coinfection | 2 | 2015 | 58 | 0.140 |
Why?
|
| Flaviviridae Infections | 1 | 2015 | 1 | 0.140 |
Why?
|
| GB virus C | 1 | 2015 | 1 | 0.140 |
Why?
|
| Ascites | 1 | 2016 | 56 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 25 | 0.140 |
Why?
|
| Internal Medicine | 2 | 2016 | 349 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 584 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 977 | 0.130 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Career Choice | 1 | 2016 | 142 | 0.130 |
Why?
|
| Comorbidity | 2 | 2015 | 944 | 0.130 |
Why?
|
| Zinc | 1 | 2015 | 92 | 0.130 |
Why?
|
| Liver Failure | 1 | 2015 | 79 | 0.120 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 7 | 0.120 |
Why?
|
| Time Factors | 4 | 2021 | 5214 | 0.120 |
Why?
|
| Middle Aged | 6 | 2021 | 25040 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 37 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 72 | 0.120 |
Why?
|
| Drug Design | 1 | 2014 | 124 | 0.120 |
Why?
|
| Male | 8 | 2021 | 40988 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 738 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 916 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 78 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2014 | 74 | 0.120 |
Why?
|
| Drug Industry | 1 | 2014 | 54 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 327 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2016 | 973 | 0.110 |
Why?
|
| Algorithms | 2 | 2020 | 1830 | 0.110 |
Why?
|
| Truth Disclosure | 1 | 2012 | 87 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 266 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1961 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 373 | 0.100 |
Why?
|
| Physicians | 1 | 2018 | 674 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 756 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 1139 | 0.090 |
Why?
|
| Hospitalization | 1 | 2016 | 851 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2015 | 2768 | 0.090 |
Why?
|
| Animals | 2 | 2023 | 26590 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2011 | 303 | 0.090 |
Why?
|
| Decision Trees | 1 | 2020 | 63 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1802 | 0.090 |
Why?
|
| Mice | 1 | 2023 | 11356 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2013 | 395 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1852 | 0.080 |
Why?
|
| Critical Illness | 1 | 2011 | 294 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1037 | 0.080 |
Why?
|
| Critical Care | 1 | 2011 | 370 | 0.080 |
Why?
|
| Prognosis | 1 | 2015 | 3680 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 610 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6513 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2021 | 816 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 508 | 0.060 |
Why?
|
| Mass Screening | 2 | 2022 | 619 | 0.060 |
Why?
|
| Aged | 4 | 2016 | 18423 | 0.060 |
Why?
|
| HIV Infections | 1 | 2013 | 772 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1169 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2023 | 130 | 0.060 |
Why?
|
| Dysbiosis | 1 | 2023 | 70 | 0.060 |
Why?
|
| Feces | 1 | 2023 | 319 | 0.050 |
Why?
|
| Adult | 3 | 2021 | 25659 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 938 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 5420 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2021 | 329 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 257 | 0.040 |
Why?
|
| Chicago | 1 | 2022 | 1380 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 885 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2021 | 429 | 0.040 |
Why?
|
| Cost Savings | 1 | 2016 | 67 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 107 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 194 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 273 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 145 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 132 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 308 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 154 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 350 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 422 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 879 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 455 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 704 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 861 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 456 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1001 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 2330 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3030 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1864 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1137 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1532 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2601 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 162 | 0.020 |
Why?
|
| Health Education | 1 | 2009 | 101 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3642 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 8496 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2271 | 0.010 |
Why?
|